Ovarian Diseases Clinical Trial
Official title:
Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders.
The aim of this study is to compare the effectiveness of testosterone,estradiol and a combined treatment with estrogens/progestagens prior to IVF-ICSI in previously diagnosed low responder patients.
During controlled ovarian hyperstimulation (COH), most of the early antral follicles are
required to grow coordinately. Marked follicular size discrepancies during COH imply that an
important number of follicles undergo unsatisfactory maturation. It has been proved that
follicular priming with estradiol during the luteal phase of the cycle prior to COH or
testosterone treatment during the early follicular phase of the COH cycle may increase the
amount of oocytes and embryos retrieved. Nevertheless there are no prospective studies
comparing such approaches. The present study consist of two phases:
The present study consists of two different phases:
- Phase I: (Non randomized) Identification of confirmed low responder patients. Potential
low responder patients will be subjected to an standardized ovarian hyperstimulation
protocol
- Phase II: (Randomized) those patients, once confirmed as low responders, will be offered
the opportunity to enter the interventional part of the study, being randomized to three
different treatment groups: estradiol, testosterone or combined progestagens and
estrogens prior to the IVF-ICSI cycle. The previous cycle (phase I) will be used as a
self-control for each patient.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
Terminated |
NCT01016054 -
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
|
Phase 1 | |
Completed |
NCT00816764 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
|
Phase 1 | |
Completed |
NCT00050414 -
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02973750 -
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
|
||
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05617755 -
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
|
Phase 1 | |
Completed |
NCT01462890 -
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
|
Phase 3 | |
Completed |
NCT01832116 -
89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
|
Phase 1 | |
Not yet recruiting |
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04189406 -
Turner Syndrome Minipuberty Study
|
||
Not yet recruiting |
NCT04579575 -
Added Value of O-RADS in Evaluation of Ovarian Lesions
|
||
Completed |
NCT04209881 -
Ovarian Reserve and Ankylosing Spondylitis
|
||
Not yet recruiting |
NCT05048654 -
A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy
|
||
Completed |
NCT03593681 -
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
|
||
Terminated |
NCT01292733 -
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
|
Phase 0 |